LV10459B - Corticued-17-alkylcarbonates, substituted in the 17-position, process for their preparation and pharmaceuticals containing them - Google Patents
Corticued-17-alkylcarbonates, substituted in the 17-position, process for their preparation and pharmaceuticals containing them Download PDFInfo
- Publication number
- LV10459B LV10459B LVP-93-302A LV930302A LV10459B LV 10459 B LV10459 B LV 10459B LV 930302 A LV930302 A LV 930302A LV 10459 B LV10459 B LV 10459B
- Authority
- LV
- Latvia
- Prior art keywords
- formula
- prednisolone
- compound
- hydrogen
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
- C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4025342A DE4025342A1 (de) | 1990-08-10 | 1990-08-10 | In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV10459A LV10459A (lv) | 1995-02-20 |
| LV10459B true LV10459B (en) | 1995-08-20 |
Family
ID=6411982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-93-302A LV10459B (en) | 1990-08-10 | 1993-05-07 | Corticued-17-alkylcarbonates, substituted in the 17-position, process for their preparation and pharmaceuticals containing them |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5362721A (xx) |
| EP (1) | EP0470617A3 (xx) |
| JP (1) | JPH0641187A (xx) |
| KR (1) | KR920004407A (xx) |
| AU (1) | AU646066B2 (xx) |
| CA (1) | CA2048841A1 (xx) |
| CZ (1) | CZ279875B6 (xx) |
| DE (1) | DE4025342A1 (xx) |
| EC (1) | ECSP941049A (xx) |
| EG (1) | EG19928A (xx) |
| FI (1) | FI913775A (xx) |
| HU (1) | HU211994B (xx) |
| IE (1) | IE912827A1 (xx) |
| IL (1) | IL99135A (xx) |
| LT (1) | LT3374B (xx) |
| LV (1) | LV10459B (xx) |
| MX (1) | MX9100613A (xx) |
| NO (1) | NO913115L (xx) |
| PT (1) | PT98605A (xx) |
| RU (1) | RU2060997C1 (xx) |
| TW (1) | TW203056B (xx) |
| ZA (1) | ZA916291B (xx) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4328819A1 (de) * | 1993-08-27 | 1995-03-02 | Hoechst Ag | Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| DE4333920A1 (de) | 1993-10-05 | 1995-04-13 | Hoechst Ag | Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| US5981517A (en) * | 1996-05-09 | 1999-11-09 | Soft Drugs, Inc. | Androstene derivatives |
| GB0019172D0 (en) * | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| ES2292604T5 (es) * | 2000-08-05 | 2015-06-01 | Glaxo Group Limited | Éster S-fluorometílico del ácido 6 ,9 -difluoro-17 -[(2-furanilcarbonil)oxi]-11 -hidroxi-16 -metil-3-oxo-androsta-1,4-dien-17 -carbotioico como agente antiinflamatorio |
| US6777399B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| CN1302007C (zh) | 2001-04-30 | 2007-02-28 | 葛兰素集团有限公司 | 具有抗炎性的在17.α位上具有环酯基的雄甾烷的17.β.－硫代羧酸酯衍生物 |
| ATE399174T1 (de) * | 2001-06-12 | 2008-07-15 | Glaxo Group Ltd | Neue anti inflammatorische 17.alpha.- heterozyklische ester von 17.beta.-carbothioat androstan derivativen |
| US20050175545A1 (en) * | 2002-02-04 | 2005-08-11 | Keith Biggadike | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
| GB0202635D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| DE602006005901D1 (de) * | 2005-02-04 | 2009-05-07 | Us Gov Health & Human Serv | NANDROLON-17ß-CARBONATE |
| GB0507165D0 (en) * | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product |
| GB0523251D0 (en) * | 2005-11-15 | 2005-12-21 | Glaxo Group Ltd | Novel compounds |
| GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
| UA116622C2 (uk) | 2011-11-11 | 2018-04-25 | Аллерган, Інк. | Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей |
| WO2023088308A1 (zh) * | 2021-11-16 | 2023-05-25 | 石家庄迪斯凯威医药科技有限公司 | 一种具有抗耐药性的抗菌化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1668079B2 (de) | 1968-01-18 | 1976-09-16 | Hoechst Ag, 6000 Frankfurt | Dialkylorthocarbonate von 17alpha, 21-dihydroxysteroiden und verfahren zu ihrer herstellung |
| DE2735110A1 (de) * | 1977-08-04 | 1979-02-15 | Hoechst Ag | Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung |
| DE2817988A1 (de) * | 1978-04-25 | 1979-11-08 | Hoechst Ag | Corticoid 17-alkylcarbonate und verfahren zu deren herstellung |
| SE449106B (sv) * | 1980-07-10 | 1987-04-06 | Otsuka Pharma Co Ltd | Steroid med anti-inflammatorisk verkan samt komposition innehallande denna |
| AU558725B2 (en) * | 1983-09-07 | 1987-02-05 | Mitsubishi Kasei Corporation | Corticoid derivatives |
-
1990
- 1990-08-10 DE DE4025342A patent/DE4025342A1/de not_active Withdrawn
-
1991
- 1991-02-22 TW TW080101348A patent/TW203056B/zh active
- 1991-08-08 RU SU915001317A patent/RU2060997C1/ru active
- 1991-08-08 IL IL9913591A patent/IL99135A/en not_active IP Right Cessation
- 1991-08-08 FI FI913775A patent/FI913775A/fi not_active Application Discontinuation
- 1991-08-08 EP EP19910113338 patent/EP0470617A3/de not_active Ceased
- 1991-08-08 CZ CS912461A patent/CZ279875B6/cs unknown
- 1991-08-08 EG EG47991A patent/EG19928A/xx active
- 1991-08-08 PT PT98605A patent/PT98605A/pt not_active Application Discontinuation
- 1991-08-08 HU HU912643A patent/HU211994B/hu not_active IP Right Cessation
- 1991-08-09 AU AU82560/91A patent/AU646066B2/en not_active Ceased
- 1991-08-09 MX MX9100613A patent/MX9100613A/es not_active IP Right Cessation
- 1991-08-09 CA CA002048841A patent/CA2048841A1/en not_active Abandoned
- 1991-08-09 NO NO91913115A patent/NO913115L/no unknown
- 1991-08-09 JP JP3223670A patent/JPH0641187A/ja active Pending
- 1991-08-09 ZA ZA916291A patent/ZA916291B/xx unknown
- 1991-08-09 KR KR1019910013758A patent/KR920004407A/ko not_active Application Discontinuation
- 1991-08-09 IE IE282791A patent/IE912827A1/en unknown
-
1993
- 1993-02-08 US US08/015,041 patent/US5362721A/en not_active Expired - Fee Related
- 1993-05-07 LV LVP-93-302A patent/LV10459B/en unknown
- 1993-06-25 LT LTIP709A patent/LT3374B/lt not_active IP Right Cessation
-
1994
- 1994-02-28 EC EC1994001049A patent/ECSP941049A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW203056B (xx) | 1993-04-01 |
| AU8256091A (en) | 1992-02-13 |
| DE4025342A1 (de) | 1992-02-13 |
| US5362721A (en) | 1994-11-08 |
| MX9100613A (es) | 1992-04-01 |
| HU912643D0 (en) | 1992-01-28 |
| IL99135A0 (en) | 1992-07-15 |
| CZ279875B6 (cs) | 1995-07-12 |
| LT3374B (en) | 1995-08-25 |
| EP0470617A3 (en) | 1992-04-01 |
| NO913115D0 (no) | 1991-08-09 |
| IL99135A (en) | 1995-12-08 |
| FI913775A0 (fi) | 1991-08-08 |
| KR920004407A (ko) | 1992-03-27 |
| RU2060997C1 (ru) | 1996-05-27 |
| HU211994B (en) | 1996-01-29 |
| PT98605A (pt) | 1992-06-30 |
| CS246191A3 (en) | 1992-03-18 |
| JPH0641187A (ja) | 1994-02-15 |
| ZA916291B (en) | 1992-04-29 |
| FI913775A (fi) | 1992-02-11 |
| HUT59155A (en) | 1992-04-28 |
| AU646066B2 (en) | 1994-02-03 |
| LV10459A (lv) | 1995-02-20 |
| IE912827A1 (en) | 1992-02-12 |
| EG19928A (en) | 1996-07-31 |
| EP0470617A2 (de) | 1992-02-12 |
| CA2048841A1 (en) | 1992-02-11 |
| LTIP709A (en) | 1995-01-31 |
| NO913115L (no) | 1992-02-11 |
| ECSP941049A (es) | 1994-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LV10459B (en) | Corticued-17-alkylcarbonates, substituted in the 17-position, process for their preparation and pharmaceuticals containing them | |
| US4242334A (en) | Corticoid 17-(alkyl carbonates) and processes for their preparation | |
| DE69710065T2 (de) | Androsten-derivate | |
| IE48328B1 (en) | Corticoid-17-(alkyl carbonates),process for their manufacture,pharmaceutical compositions containing them and their use in the treatment of inflammatory dermatitis | |
| Ueno et al. | Synthesis and evaluation of antiinflammatory activities of a series of corticosteroid 17. alpha.-esters containing a functional group | |
| JPH08508278A (ja) | 新規プレドニソロン誘導体 | |
| US5091380A (en) | N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors | |
| Shapiro et al. | 17-Heteroaroyl esters of corticosteroids. 2. 11. beta.-Hydroxy series | |
| JPH02268195A (ja) | １７位置にアミノ置換鎖を有する新規の３―ケトステロイド、それらの製造方法及びこの方法の中間体、それらの薬剤としての使用並びにそれらを含有する製薬組成物 | |
| JPS6411037B2 (xx) | ||
| KR100450854B1 (ko) | α-17치환체가없는신규의프레그난유도체,이들의의약용도,제조방법,및이의중간체및관련화합물 | |
| FI57114C (fi) | Foerfarande foer framstaellning av nya vid cancerterapi anvaendbara terapeutiskt vaerdefulla enolestrar av steroider | |
| NO165679B (no) | Analogifremgangsmaate for fremstilling av nye, terapeutiskvirksomme androstan-17beta-karboksyl-syreestere. | |
| US5196411A (en) | 17β-acyl-3-carboxy-androsta-3,5-dienes as testosterone 5α-reductase inhibitors | |
| US4176126A (en) | Novel corticoids | |
| US5075450A (en) | Intermediates in the synthesis of 17β-acyl-3-carboxy-androsta-3,5-dienes | |
| JP2007507467A (ja) | 誘導性ｎｏシンターゼ阻害剤としてのイミダゾピリジン誘導体 | |
| JPH0592989A (ja) | テストステロン ５α−還元酵素阻害剤としての１７β−アシル−３−カルボキシ−アンドロスタ−３，５−ジエン類 | |
| HU208152B (en) | Process for producing 19-norprogesterone derivatives alkylated in 17/21-position and pharmaceutical compositions comprising such compounds | |
| PT708111E (pt) | 21 ¬0|-esteres de 17-desoxicorticosteroides processo para a sua preparacao e medicamento que os contem | |
| US4079054A (en) | 7α-Halogeno-3-oxo-1,4-pregnadiene-21,17β-carbolactones and related compounds | |
| JPH046200B2 (xx) | ||
| KR810000582B1 (ko) | 코르티코이드 17-(알킬 카보네이트)류의 제조방법 | |
| US3641005A (en) | Process for the preparation of delta**4-6 6-difluoro - 320 - diketo - 17alp ha21-dihydr-oxypregnenes | |
| AU2020274362A1 (en) | Substituted fluorine-containing imidazole salt compound, preparation method therefor, pharmaceutical composition thereof and use thereof |